7,600 Corcept Therapeutics Incorporated $CORT Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al trimmed its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 28.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,974 shares of the biotechnology company’s stock after selling 7,600 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Corcept Therapeutics were worth $2,186,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Corcept Therapeutics in the second quarter valued at approximately $27,000. State of Wyoming raised its position in Corcept Therapeutics by 29.5% in the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 186 shares during the last quarter. Gould Capital LLC raised its position in Corcept Therapeutics by 66.7% in the 1st quarter. Gould Capital LLC now owns 1,000 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 400 shares during the last quarter. IFP Advisors Inc lifted its holdings in Corcept Therapeutics by 568.4% during the 2nd quarter. IFP Advisors Inc now owns 909 shares of the biotechnology company’s stock worth $79,000 after buying an additional 773 shares in the last quarter. Finally, Root Financial Partners LLC acquired a new position in Corcept Therapeutics during the 3rd quarter worth $85,000. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Corcept Therapeutics

In other news, insider Roberto Vieira sold 8,333 shares of the stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $116.10, for a total value of $967,461.30. Following the transaction, the insider owned 3,946 shares of the company’s stock, valued at $458,130.60. This represents a 67.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Joseph Lyon sold 9,190 shares of the stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $116.13, for a total value of $1,067,234.70. Following the completion of the transaction, the insider directly owned 5,683 shares in the company, valued at approximately $659,966.79. This trade represents a 61.79% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 349,203 shares of company stock worth $40,686,076 over the last quarter. 20.70% of the stock is currently owned by insiders.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Corcept reported Q3 revenue of about $340.5 million, above the roughly $336.4 million consensus, and earnings of $1.01 per share, beating the $0.79 estimate cited in the results coverage. Earnings were also up from $0.16 per share a year earlier. The revenue and earnings beats are positive signals for the business. Corcept’s Q3 2026 beats on revenue
• Neutral Sentiment: The company also announced its third-quarter financial results and provided a corporate update; the available coverage does not specify additional details from that update that would clearly change the investment outlook. Corcept Announces Third Quarter Results and Corporate Update
• Negative Sentiment: Despite the earnings beat, one report said CORT shares sold off. The coverage does not identify a specific cause, suggesting the strong results were not enough to satisfy investor expectations or overcome other market concerns. Q3 Earnings Beat, Shares Still Sold Off

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $81.93 on Wednesday. The stock has a market cap of $8.86 billion, a price-to-earnings ratio of 191.57 and a beta of 0.54. The company has a 50 day moving average of $110.31 and a 200-day moving average of $75.06. Corcept Therapeutics Incorporated has a one year low of $28.66 and a one year high of $126.38.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Tuesday, November 3rd. The biotechnology company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.22. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The business had revenue of $340.47 million for the quarter, compared to analyst estimates of $336.37 million. During the same period in the prior year, the business posted $0.16 earnings per share. Corcept Therapeutics’s revenue was up 64.0% compared to the same quarter last year. Equities research analysts anticipate that Corcept Therapeutics Incorporated will post 1.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Wall Street Zen upgraded Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Weiss Ratings upgraded Corcept Therapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. HC Wainwright restated a “buy” rating and set a $165.00 target price on shares of Corcept Therapeutics in a research report on Friday, September 18th. Canaccord Genuity Group upped their price target on Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Finally, Zacks Research cut Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 27th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Corcept Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $138.17.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.